The landscape of inherited retinal diseases (IRDs) is continuously evolving, bringing renewed hope to patients and families affected by these debilitating conditions. Recent advancements include the FDA approval of a first-of-its-kind eye implant designed to slow vision loss in a rare eye disease, and significant investments in optogenetics, a promising gene therapy approach. These developments highlight the accelerating progress in both neuroprotection and vision restoration strategies for IRDs.
FDA Approves ENCELTO for Macular Telangiectasia Type 2
In a landmark decision, the U.S. Food and Drug Administration (FDA) approved ENCELTO (revakinagene taroretcel-lwey) in March 2025, marking the first-ever approved treatment to slow vision loss in adults with idiopathic macular telangiectasia type 2 (MacTel). MacTel is a rare, progressive neurodegenerative eye disease that primarily affects the macula, leading to a gradual and irreversible deterioration of central vision.
ENCELTO is a surgically implanted device that utilizes an encapsulated cell therapy platform to deliver a continuous, sustained dose of ciliary neurotrophic factor (CNTF) directly to the retina. CNTF is a naturally occurring protein that acts as a neuroprotectant, supporting the survival and health of nerve cells, including the light-sensing photoreceptors in the retina. By shielding these cells from damage, ENCELTO aims to delay the degenerative process and slow the loss of macular photoreceptors. The approval was based on two Phase 3 clinical studies demonstrating that the implant significantly slowed the loss of these critical retinal cells over a 24-month period. ENCELTO is expected to be available to U.S. patients starting in June 2025.
Novartis Boosts Optogenetics Portfolio for Broad IRD Treatment
Further demonstrating the commitment to addressing IRDs, Novartis acquired Arctos Medical in September 2021, significantly expanding its optogenetics portfolio. Optogenetics is an innovative gene therapy approach that aims to restore vision by making surviving retinal cells light-sensitive, particularly in advanced stages of retinal degeneration where photoreceptors have been lost.
Unlike traditional gene therapies that target specific genetic mutations, optogenetics offers a gene-agnostic solution, meaning it could potentially treat many forms of IRDs regardless of the underlying genetic cause. Arctos' proprietary technology involves delivering a light-sensitive optogene to specific retinal cells using gene therapy, effectively transforming them into replacement photoreceptor-like cells. This approach holds immense promise for patients who are legally blind due to photoreceptor loss, including those with conditions like retinitis pigmentosa and age-related macular degeneration. While still in preclinical stages at the time of acquisition, this investment underscores the potential of optogenetics to offer a broad therapeutic option for severe vision loss.
A Future of Expanding Treatment Options
These recent developments signify a pivotal moment for individuals living with inherited retinal diseases. The FDA approval of ENCELTO provides a much-needed treatment for MacTel, demonstrating the success of neuroprotective strategies. Concurrently, the significant investment in optogenetics by companies like Novartis highlights the growing potential for gene-agnostic therapies to restore vision in a wider range of IRDs.
The progress in both slowing disease progression and exploring new avenues for vision restoration offers substantial hope. As research continues to advance, the future promises an expanding array of therapeutic options, moving closer to a reality where the impact of inherited retinal diseases can be significantly mitigated, and for some, vision potentially restored. The ongoing clinical trials and research in gene therapy and cell-based treatments continue to push the boundaries of what is possible in ophthalmology.